By Daniella Parra Vinson & Elkins said it is representing L3Harris Technologies (NYSE: LHX) in connection with its proposed partnership with the U.S. Department of War. L3Harris and the DoW agreed to the terms of a proposed DoW investment in...

Download the Complete Report Here By Brandon Hornback SOL Strategies Inc. (NASDAQ: STKE) finished 2025 on a high note, validating the ongoing shift from a passive crypto holder to an institutional-grade Solana infrastructure platform. The company’s DAT++ strategy is now...

By Karen Roman Vinson & Elkins said it represented JPMorgan Chase & Co. (NYSE: JPM) as financial advisor to The Saudi Basic Industries Corporation in the $450 million sale of its regional engineering thermoplastics business in the Americas and Europe...

IPO Edge and CorpGov will be conducting interviews from the floor of the New York Stock Exchange on Feb. 3, 2026. We invite guests to join 15-minute fireside chats recorded in a multi camera high-definition television studio at the NYSE. All content...

By Karen Roman Ascentage Pharma Group Internat (Nasdaq: AAPG) said its treatment candidate for B-cell diseases APG-3288 was granted the investigational new drug clearance by the FDA. The company will also conduct a global Phase I study evaluating APG-3288 in...

By Karen Roman Vinson & Elkins said Vinay Prabhakar is its new partner at the firm’s tax practice in New York, having previously served as Managing Director and Head of Tax at Global Infrastructure Partners (GIP), now part of BlackRock,...

By Exec Edge Editorial Staff Behind every scientific breakthrough at Colossal Biosciences stands a question that transcends technology: Should we? While genetic engineering capabilities have advanced dramatically, the ethical frameworks ensuring responsible use remain paramount. For Colossal’s de-extinction work—including the...

By Exec Edge Editorial Staff John McEntee, the former University of Connecticut quarterback who went on to become a key political figure in U.S. Conservative politics under President Donald Trump, has made a substantial financial contribution to UConn’s football program,...

By Karen Roman Biopharmaceutical company Medera Inc. said it completed patient enrollment for Cohort B of its clinical trial evaluating SRD-002 gene therapy for heart failure with preserved ejection fraction (HFpEF). This milestone allows Medera to advance to Phase 2b...

The Dubai royal’s investment approach through Inmā Emirates Holdings demonstrates how patient capital and technology transfer can generate measurable social impact across emerging markets By Exec Edge Editorial Staff The language of impact investing has evolved from philanthropic experiment to...